Benznidazole is one of the two existing anti-parasitic drugs for Chagas' disease treatment. However, it is a poorly tolerated drug and its use to treat chronic disease raises safety concerns. Knowledge about its toxicity profile is scarce and mostly based on post-marketing observational studies.
In order to provide a systemic evaluation of safety of benznidazole in chronically infected adults, the authors of the study combined data from two prospective clinical trials performed in 2013 and 2016 at the Hospital Clinic of Barcelona, designed to assess the safety of the drug produced by ELEA Laboratories, Argentina. Adverse reactions were observed in 85 of the 99 participants, with an average of three adverse reactions per patient. Most adverse reactions (90%) were mild and appeared in the first month of treatment. The researchers also identified some unexpected adverse reactions that were not described previously, such as sleeping disorders and anxiety.
"These results confirm that, with the most widely used dosage and regimen, there is a high frequency of adverse reactions to benznidazole" says Maria Jesús Pinazo, ISGlobal researcher and study co-author. "Until we have something better, benznidazole will remain part of the treatment in the near future, so these results underline the urgent need to find ways to combine it with other drugs or use different dosages in order to achieve maximum efficacy with the minimum toxicity," she adds.
Chagas Disease is caused by the protozoan T. cruzi and is most frequently transmitted through an insect vector (the kissing bug). However, transmission from mother to child or through blood or organ donations can also occur. An estimated 6 million to 7 million people worldwide are infected with T. cruzi and up to 20 percent to 30 percent of them could develop cardiac disease if left untreated.
Source: Barcelona Institute for Global Health
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.
A Helping Hand: Innovative Approaches to Expanding Hand Hygiene Programs in Acute Care Settings
July 9th 2025Who knew candy, UV lights, and a college kid in scrubs could double hand hygiene adherence? A Pennsylvania hospital’s creative shake-up of its infection prevention program shows that sometimes it takes more than soap to get hands clean—and keep them that way.